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ORIGINAL RESEARCH
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Stephanie D. Nichols PharmD BCPS BCPP,5,6,7  Kenneth L. McCall PharmD,5 Brian J. Piper PhD MS1,8
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Introduction:  The Diversion Alert Program (DAP) was established to curb misuse of drugs and help identify people 
who may need treatment for substance use disorder (SUD). Law enforcement compiled arrest data 
into a database accessible by health care providers. Our objectives were to identify regional and 
demographic differences in drug use and misuse in Maine.
Methods:  All arrests (N = 11 234) reported to the DAP from 2013 to 2018 were examined by county and arrestee 
demographics, and classified into families (opioids, stimulants, sedatives). The Drug Enforcement 
Administration’s Automation of Reports and Consolidated Orders System (ARCOS) tracks the 
distribution of controlled pharmaceuticals (Schedule II-III). Opioids were converted to oral morphine 
milligram equivalents (MMEs). County and zip-code maps were constructed.
Results:  The most arrests per capita occurred in Androscoggin, Knox, and Cumberland Counties. Opioids were 
the most common drug class in arrests in all counties except Aroostook County, where stimulants 
were most common. Medical distribution of opioids varied. Although buprenorphine doubled, many 
prescription opioids (eg, hydrocodone, fentanyl, oxymorphone) exhibited large (> 50%) reductions in 
distribution. Methadone was the predominant opioid statewide (56.4% of total MMEs), although there 
were sizable differences between regions (Presque Isle = 8.6%, Bangor = 78.9%). Amphetamine 
distribution increased by 67.9%.
Discussion:  The DAP, a unique pharmacoepidemiological resource, revealed a 6-fold difference in drug arrests 
by county. Regional differences in methadone may be due to heterogeneities in methadone clinic 
distribution.
Conclusions:  The decrease in most prescription opioids, but increase in prescription stimulants, may warrant 
continued monitoring to improve public health.
Keywords:  demographic differences, arrests, Maine, opioids, stimulants
In the New England states, the morphine milligram equivalents (MMEs) prescribed per person were among the highest in the United States. In 2016, 
Maine was ranked fifth nationally at 1393 MME, 
which increased to 2000 MME when opioid use 
disorder (OUD) medications, buprenorphine and 
methadone, were included.1 Importantly, more 
than 80% of people who use heroin started with 
prescription opioids.2 Over the past 2 decades, 
opioid prescribing patterns differed appreciably 
in the United States. In states such as Maine, 
West Virginia, Kentucky, prescribing rates in the 
late 1990s were 2.5 to 5.0 times higher than the 
national average for hydrocodone and oxycodone.3 
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States with a higher median age, such as Maine, 
also used more prescription opioids in general.1 
Cumberland County, containing Maine’s largest city 
of Portland, accounted for 60% more drug-related 
deaths from 1997 to 2002 than would be anticipated 
based on the population. This percentage indicates 
an ongoing issue that has been plaguing the region. 
Based on Maine’s medical examiner reports, 
methadone, oxycodone, fentanyl, hydrocodone, 
and other prescription opioids were the drugs most 
often mentioned on death certificates in the last 2 
decades.4 Drug fatalities in years as recent as 2019 
continued to involve opioids in 84% of the cases. 
These fatal overdoses typically occurred with other 
substances, including fentanyl analogs, which have 
been on the rise since 2013.5,6 Innovative strategies 
are needed to address this ongoing public health 
crisis.
Maine had a novel database, the Diversion Alert 
Program (DAP), which originated in Aroostook 
County and was expanded statewide to improve 
communication between law enforcement and 
health care providers. The DAP included arrestee 
names, dates of birth, towns of residence, drug 
charges, implicated drugs, and arresting agency 
for adults whose arrest involved illicit substances, 
prescription medications, and non-prescription 
pharmaceuticals.7 As a point-of-care tool, this 
resource could be used to help identify patients who 
might have needed specialist (eg, pain, psychiatry, 
or addiction medicine) involvement. The DAP was 
also used as a pharmacoepidemiological source, 
with regular reports for 2014 through 2017.3,5,7,8,9 The 
predominant substances involved in arrests were 
heroin, cocaine and crack cocaine, buprenorphine, 
oxycodone, methamphetamine, alprazolam, 
clonazepam, marijuana, hydrocodone, fentanyl, 
amphetamine, α-pyrrolidinovalerophenone (or bath 
salts), and gabapentin. Possession accounted for 
most (three-fifths) charges, followed by trafficking. 
Older adults (≥ 60 years old) had a significant 
and disproportionate percentage of their arrests 
involving oxycodone and hydrocodone.8 The annual 
reports showed that Cumberland and Androscoggin 
Counties led the state on population-corrected 
arrests.7,8
The first objective of this study was to analyze 
nonmedical use of controlled substances at a 
county level as reported by the DAP. The second 
objective was to examine whether the arrest profile 
differed by arrestee demographics, specifically 
their biological sex and age. The third objective 
was to use a comprehensive data source, the Drug 
Enforcement Administration’s (DEA) Automation 
of Reports and Consolidated Ordering System 
(ARCOS) to determine regional changes in medical 
use of controlled substances in Maine. Collectively, 
we aimed to identify which recreational and medical 
drugs and drug classes are of concern, and to reveal 
the demographic and regional profile of those at risk 
for substance misuse in Maine.
METHODS
Procedures
Two complementary data sources were used: the 
DAP and ARCOS. The sample included all arrests 
(N = 11 234) reported to the DAP from 2013, when 
the program expanded statewide, to March 2018, 
when the program ceased operation due to lack of 
funding. Local, state, and federal law enforcement 
agencies provided information. A de-identified 
spreadsheet containing information on age, sex, 
county of arrest (Supplemental Figure 1), substance, 
and offense was obtained. A prior study determined 
that, overall, possession accounted for 60.0% of 
arrests, followed by trafficking (24.5%), distribution 
(3.9%), and possession with intent to distribute 
(3.5%); however, this general pattern differed 
considerably by agent.9 Arrest data was classified 
by the arrestee’s county of residence. State and 
county values were calculated for the following 
categories: total number of arrests, total population, 
percentage of county population arrested, 
percentage of arrests involving females, mean 
age of total arrests, percentage of arrests involving 
opioids or stimulants, most frequent federal drug 
schedule, and most common level (federal, state, 
county, or city) of arresting agency. For simplicity, 
county and city agencies are henceforth designated 
as “local.” Additional information, including the 
processing steps for arrests involving multiple 
drugs, is available elsewhere.7
The DEA’s ARCOS is a federal program created with 
the 1970 Controlled Substances Act that collects 
data (weight distributed in grams) of Schedule 
II and III substances distributed to pharmacies, 
hospitals, methadone treatment programs (referred 
to by the DEA as narcotic treatment programs), 
and providers.10 From 2008 to 2017, the program 
evaluated 13 opioid pain medications (oxycodone, 
fentanyl, morphine, hydrocodone, hydromorphone, 
oxymorphone, tapentadol, codeine, meperidine, 
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dihydrocodeine, sufentanil, remifentanil, and 
alfentanil), and 2 opioids used primarily for OUD 
(methadone and buprenorphine). The oral MME 
conversion factors (eg, tapentadol = 0.4, methadone 
= 10) are available elsewhere.3 The weights 
distributed of stimulants (eg, methylphenidate, 
amphetamines, lisdexamfetamine) and barbiturates 
(eg, pentobarbital, secobarbital) were also obtained. 
ARCOS was previously validated by comparing 
results for a single opioid with that obtained for 
the Maine Prescription Monitoring Program, which 
revealed a high correlation (r = 0.985).1 Similarly, 
when classifying areas into high versus low 
stimulant use, ARCOS showed a high agreement 
(96.4%) with the California Prescription Monitoring 
Program.11 Procedures were approved by the ethics 
committee of the University of New England.
Data analysis
The rate of arrests per county was determined 
by taking the total number of arrests by the years 
DAP was operational statewide (4.75), dividing that 
number by the population in 2015 (ie, the midpoint 
year)11, and multiplying that value by ten-thousand. 
Maine’s population increased by 1.3% from 2008 
to 2017. The percentage of all arrests involving 
females was calculated by dividing the number of 
female arrestees by the total number of arrests for 
each county. The percentage of arrests involving 
opioids or stimulants were calculated by dividing 
the number of arrests involving each drug class by 
the number of arrests in the county. ARCOS also 
reports drug distribution by the first 3 digits of the zip 
code. For simplicity, 039 = York, 040 = Kennebunk, 
041 = Portland, 042 = Lewiston, 043 = Augusta, 
044 = Bangor, 045 = Boothbay Harbor, 046 = Bar 
Harbor, 047 = Presque Isle, 048 = Rockport, and 
049 = Waterville. Geographic differences in the total 
MME for each opioid were expressed by dividing 
the highest percentages by the lowest percentages 
based on area (eg, 50% in county A/10% in county 
B = a 5-fold difference). The locations of the 
methadone clinics were obtained (August 2020). 
Relative to their peak year, arbitrary categories 
were interpreted as small (0% to 19.9%), medium 
(20.0% to 49.9%), and large (≥ 50.0%) changes in 
controlled substance weight per year. County maps 
were generated with Microsoft Excel and QGIS.
RESULTS
Diversion Alert Program
Between 2013 and 2018, a total of 11 234 drug-
related arrests were reported to the DAP. A 5.6-
fold difference in the rate of arrests, corrected 
for population, occurred in Androscoggin County 
(26.9) relative to Piscataquis County (4.8). In 
Androscoggin County, 35.2% of the arrested 
population was female, compared to 42.5% in 
Lincoln County. The median age of arrestees 
differed by 6 years in Somerset County (35 years 
old) compared to Piscataquis County (29 years 
old). Among the 16 counties, 15 reported more 
opioid arrests than stimulant arrests. Counties 
with the greatest percentage of arrests involving 
opioids were Knox County (57.0%), Waldo County 
(56.8%), Kennebec County (55.9%), and Hancock 
County (55.6%). Stimulants accounted for fewer 
than one-eighth of arrests (11.7%) in Waldo and 
Lincoln Counties versus almost two-fifths (38.7%) 
in Aroostook County. Schedule II substances 
(e.g., cocaine) were most common in 13 (81.25%) 
counties. State agencies were responsible for most 
arrests in more than half (56.3%) of the counties 
(Table 1).
DEA’s Automated Reports and Consolidated 
Orders System
Medical distribution of opioids, as defined by MME, 
increased in 2008 (2944.8 kg), peaked in 2010 
(3207.5 kg), and declined through 2017 (2236.0 
kg). A steep decline occurred from 2016 to 2017. 
Opioids primarily used for pain accounted for one-
third of the total MME distributed in Maine in 2008 
(32.4%). Distribution of analgesic opioids increased 
to 36.5% in 2012 before receding to 26.2% in 2017 
(Figure 1, Panel A).
Figure 1, Panel B shows the dynamic changes in 
the distribution of individual opioids standardized 
to MME. Except for buprenorphine distribution, 
which doubled between 2008 and 2017, all 
other prescription opioids decreased over time. 
Relative to their peak years over the past decade, 
hydromorphone, methadone, codeine, oxycodone, 
and morphine have undergone moderate reductions 
in distribution. Oxymorphone, tapentadol, fentanyl, 
hydrocodone, and meperidine had large reductions. 
Lisdexamfetamine distribution increased 6.9-fold 
between 2008 and 2017 (9.8 kg). Figure 1, Panel C 
shows changes in other opioids during this period. 
Methylphenidate distribution had a small (-10.1%) 
decline since peaking in 2012 (157.0 kg) (Figure 
1, Panel D). Amphetamine distribution greatly 
increased (+67.9%) between 2008 and 2017 (54.0 
to 90.7 kg). Pentobarbital distribution remained 
relatively constant over the decade (79.9 kg in 2008 
and 80.9 kg in 2017) (data not shown), whereas 
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Table 1. Maine Diversion Alert Program Arrests from June 2013 to March 2018
County
Number  



























Androscoggin 1372 107 233 26.9 35.2 31 42.1 35.9 2 Local
Knox 430 39 855 22.7 31.6 31 57 17.9 2 State
Cumberland 3000 289 361 21.8 28.8 31 35.1 25.8 2 Local
Aroostook 693 68 824 21.2 27.9 31 27.6 38.7 2 State
Washington 313 31 625 20.8 41.9 35 47.3 18.9 2 Local
Lincoln 315 33 969 19.5 42.5 32 46 11.7 2 State
Penobscot 1400 152 692 19.3 29.5 31 44.7 29.6 2 Local
Waldo 352 39 155 18.9 32.4 31 56.8 11.7 2 State
Kennebec 932 119 980 16.4 35.6 31 55.9 24.7 1 Local
Hancock 417 54 659 16.1 35.7 32 55.6 20.4 2 State
Sagadahoc 210 35 113 12.6 28.1 32 42.4 17.6 1 State
Oxford 323 57 202 11.9 33.7 32 48.9 21.7 2 State
Somerset 285 50 745 11.8 25.6 35 51.2 27 2 Local
York 1038 201 169 10.9 32.5 31 54 22.5 1 State
Franklin 115 30 072 8.1 35.7 30 37.4 22.6 2 State
Piscataquis 39 16 935 4.8 35.9 29 51.3 20.5 2 Local
*Rate is the number of arrests per year divided by the population size in 2015 and multiplied by ten-thousand.
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Figure 1. Distribution of Opioid Use. (Panel A) Total morphine milligram equivalents (MME) per year 
for opioids for pain (oxycodone, fentanyl, morphine, hydrocodone, hydromorphone, oxymorphone, 
tapentadol, codeine, and meperidine), opioid use disorder (OUD; methadone and buprenorphine), and all 
11 agents. (Panels B-D) Raw weights of the most common opioids (Panel B), other opioids (Panel C), and 
stimulants and secobarbital (Panel D) as reported by the Drug Enforcement Administration’s Automated 
Reports and Consolidated Orders System10 in Maine from 2008 to 2017. Percent change relative to the 
peak year is shown in parentheses.
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secobarbital distribution precipitously decreased 
from rare (109.9 g in 2008) to unavailable (0.0 g in 
2016 and 2017).
Further analysis was completed on 11 opioids, 
expressed as a percentage of the total MME, in 
2017 by 3-digit zip code. This analysis revealed 
pronounced geographical variations relative to 
the location of methadone clinics (Figure 2). 
Methadone was the predominant opioid statewide, 
accounting for a 3-fold greater percentage of the 
total relative to buprenorphine (Figure 2, Panel 
A). Opioids used primarily for OUD accounted 
for most opioids distributed in the Bar Harbor 
(75.0%), Rockland (85.2%), and Bangor (87.4%) 
zip codes, likely due to the presence of one or 
more methadone treatment programs in Rockland 
and Bangor. Methadone was responsible for one-
fifth or less of opioids in York (21.0%), Boothbay 
Harbor (12.6%), and Presque Isle (8.6%) (Figure 
2, Panel B). Zip-code level heterogeneities were 
9.2-fold for methadone, 9.5-fold for morphine, 6.2-
fold for fentanyl, 5.7-fold for oxycodone, and 4.9-
Figure 2. Geographical Variation in Opioid Use in Maine in 2017. Statewide percentage of the total 
morphine milligram equivalent by opioid is shown for the state overall (Panel A). The other category includes 
tapentadol, meperidine, oxymorphone, and codeine.
Statewide percentage of the total morphine milligram equivalent for specific opioids according by 3-digit 
zip codes (Panels B-F) are shown with color gradation reflecting the specific opioid noted.  The location of 
methadone clinics (labeled M) are shown, as reported to the Drug Enforcement Administration’s Automation 
of Reports and Consolidated Orders System.¹⁰ 
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fold for buprenorphine. Hydrocodone accounted for 
an 8-fold greater portion of the total in Presque Isle 
(9.9%) relative to Portland (1.1%) (data not shown).
DISCUSSION
The first 2 objectives of this study were to examine 
county and demographic differences in controlled 
substance misuse in Maine. The rate of arrests 
showed 6-fold differences based on county. Except 
for Aroostook County, which was more impacted 
by stimulants, the state was very homogeneous in 
which drug class (opioids) was related to the most 
arrests. Examining controlled substance distribution 
over time revealed that prescription opioids peaked 
in 2010 and subsequently declined, particularly in 
2016 and 2017. This study also determined that 
the geographical differences in which prescription 
opioids were most common by MME was associated 
with the location of methadone clinics. These 
facilities were not distributed uniformly statewide, 
as 25% of the state’s total were in Penobscot 
County and 33% were in Cumberland County.13
This regional analysis extends our prior research 
that emphasized broader state-level patterns.9 
The DAP provided information that complemented 
Prescription Monitoring Programs (PMPs) 
for patient care. However, the DAP was also 
invaluable for research and could complement 
other data sources, such as self-report from the 
National Household Survey on Drug Use and 
Health or Monitoring the Future, emergency room 
reports, and drug seizures.12 A key theme in prior 
reports was the substantial diversity of substances 
implicated in arrests beyond the “usual suspects” 
of heroin, oxycodone, hydrocodone, illicit fentanyl, 
methamphetamine, and cocaine. Hundreds 
of arrests were related to benzodiazepines 
(eg, alprazolam, clonazepam), marijuana, and 
miscellaneous prescription pharmaceuticals that 
were non-controlled (eg, gabapentin, quetiapine).9
Our analysis revealed that almost 10-fold 
more arrests involved buprenorphine (812) 
than methadone (82). These data suggest the 
need to improve supervision and monitoring of 
prescribed buprenorphine, or the ongoing need 
for more access to buprenorphine prescribers. 
The disparity was striking given that, on an MME 
basis, methadone was distributed statewide over 
3-fold more than buprenorphine. However, these 
data can be explained, in part, by considering the 
distribution of methadone for patients with OUD. 
Due to federal regulations, addiction medicine 
providers typically dispense daily methadone doses 
onsite at methadone clinics. To date, Maine has 12 
methadone clinics in 9 counties.13 These clinics 
contain providers who specialize in medically 
treating patients with OUD, especially methadone, 
and with providing counseling services.
A high rate of buprenorphine arrests may still be 
surprising, given the drug’s pharmacology as a partial 
mu-receptor agonist. Buprenorphine has a safety 
profile that is considerably more favorable than that 
of methadone: LD50 = 235 mg/kg (buprenorphine) 
vs 23 mg/kg (methadone) when given intravenously 
in rats.14 Yet, 11 000 poison-control reports still 
involved buprenorphine, primarily as a monotherapy 
product, among children and adolescents (< 19 
years old) from 2007 to 2016.15 Buprenorphine 
was identified as a potentially contributing factor 
in 22 drug deaths in Maine in 2017.16 In other 
states, such as Wisconsin, law enforcement 
identified an increased number of cases of driving 
under the influence of buprenorphine, often with 
benzodiazepines.17 Although both methadone and 
buprenorphine are efficacious for OUD treatment, 
the provision of methadone for OUD is considerably 
more restricted than buprenorphine. A systematic 
review identified better retention in OUD treatment 
with methadone than buprenorphine/naloxone18, 
however buprenorphine prescribing practices have 
evolved significantly in the past decade. Methadone 
accounted for one-eighth of the total opioid MME 
in Presque Isle and Boothbay Harbor but three-
quarters in Bangor and Portland. Methadone 
treatment programs in Maine increased from 9 in 
2008 to 10 in 2017.10 Almost two-thirds of patients 
in opioid treatment programs resided in only 3 
counties (Penobscot County = 33%, Cumberland 
County = 22%, and Washington County = 8%).19 
Although there is room for improvement, Maine 
ranked second in the United States for the most 
waivered physicians for buprenorphine per capita.20
Pronounced reductions in opioid distribution over the 
past decade have been reported.21 Perhaps, more 
novel is the rate of change in opioid use, particularly 
from 2015 to 2017. Liberal practices in prescribing 
opioids during the 2000s was the unfortunate result 
of a confluence of factors.7 We suspect that the 
return to more judicious and evidence-based use 
of opioids, particularly minimizing use in patients 
with chronic non-cancer pain, may also reflect 
the convergence of multiple policy and incentive 
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changes at the federal, state, and local level. In 
January 2017, Maine’s “An Act to Prevent Opiate 
Abuse by Strengthening the Controlled Substances 
Prescription Monitoring Program” took effect. This 
act was unusual for a state prescribing law because 
it included fiscal penalties for non-adherence. Maine 
had a significantly greater decrease in prescription 
opioids than several other New England (CT, 
MA, RI, VT) and mid-Atlantic states (NY, PA) that 
enacted similar opioid prescribing laws that lacked 
penalties.21 In the year that followed, between 2017 
and 2018, drug-related deaths involving prescription 
opioids in Maine declined by 37%.16
Three other findings are noteworthy. The 
substantial increase in lisdexamfetamine and other 
amphetamine distribution extend earlier national 
data.7 ARCOS, and DAP, do not provide information 
about whether the original source of these stimulants 
was for attention deficit hyperactivity disorder in 
children or adults, obesity, post-traumatic brain 
injury, or another indication. The ratio of males 
to females for drug-related deaths in Maine was 
2.51 to 1 in 20175 and 2.45 to 1 in 2018.16 Among 
arrestees, the ratio was similar (2.14 to 1). Together 
with other arrest data, these findings indicate that 
sex differences in drug misuse may be gradually 
declining.17
Some strengths and limitations of these datasets are 
noteworthy. The DAP was unique to Maine and, to 
our knowledge, has not been emulated elsewhere, 
which precludes comparisons with other states. 
Reporting to the DAP was voluntary, and some 
agencies (eg, tribal police) infrequently submitted 
arrest information, which is a caveat in interpreting 
data in Table 1. Similarly, some individuals may have 
been arrested multiple times over a 6-year period. 
Although we cannot account for this factor in a de-
identified research database, we do not believe 
it would impact southern versus northern Maine 
counties differently. It is important to emphasize 
that there are key differences between an arrest 
and a subsequent conviction, and data regarding 
conviction is unknown. It is also unknown how 
often field tests, whose specificity is questionable, 
were used to determine the presumptive substance 
identity.22 Finally, there is a potential for bias in DAP 
regarding populations that are more likely to be 
surveilled by law enforcement and subsequently 
arrested, such as those with a history of opioid 
overdose or diagnosed OUD. Socioeconomic 
and racial disparities might also contribute to 
bias. Unlike PMPs, ARCOS is comprehensive in 
its coverage of Schedule II substances. ARCOS 
reports by substance weight instead of using 
perhaps more intuitive units of analysis, such as 
prescriptions. Methadone was the most prevalent 
opioid by MMEs.3,23 The 42 CFR Part 2 prevented 
methadone, when used by methadone treatment 
programs, from being entered into the state PMP 
results. Although arguably well-intentioned, this 
federal regulation is a key caveat when interpreting 
other pharmacoepidemiological research,8,24 and 
some have advocated that this regulation be 
updated.25
CONCLUSIONS
The DAP was an important information-sharing and 
pharmacoepidemiological resource that was unique 
to Maine. This study identified a 6-fold difference 
in arrest rates by county. There were also sizable 
differences in drug arrests involving opioids and 
stimulants by county. A better understanding of the 
pronounced regional differences in prescription 
drug distribution and arrests may improve targeted 
public health interventions, including education and 
access to treatment. We are cautiously optimistic 
that the DAP could be integrated with PMPs and 
implemented in other states. Continued monitoring 
of trends in arrests, prescription use, and misuse is 
warranted. Further, limiting access by adolescents 
and persons with SUD to prescription opioid 
analgesics and other misusable substances should 
be a continued priority.
Acknowledgements: This research was 
supported by the Fah-Beck Fund for Research 
and Experimentation and the Health Resource and 
Services Administration (D34HP31025). Maureen 
J. Murtha and Salomey O. Mensah facilitated the 
summer team.
Disclosures: BJP has osteoarthritis research 
supported by Pfizer. A member of his household was 
previously employed by Garlic Acres, a company 
that produced medical cannabis products. SDN has 
consulted for Shire. MF and CED were employed 
by the Diversion Alert Program. The other authors 
have no disclosures.
Preliminary versions of this data have been presented 
at the 2019 GCSoM Summer ResearchrImmersion 
Program.
8
Journal of Maine Medical Center, Vol. 3 [2021], Iss. 2, Art. 2
https://knowledgeconnection.mainehealth.org/jmmc/vol3/iss2/2
DOI: 10.46804/2641-2225.1074
Procedures were approved by the IRB of the 
University of New England (#20180410-009). 
REFERENCES
1. Piper BJ, Shah DT, Simoyan OM, McCall KL, Nichols 
SD. Trends in medical use of opioids in the U.S., 2006-
2016. Am J Prev Med. 2018;54(5):652-660. doi:10.1016/j.
amepre.2018.01.034
2. Jones CM. Heroin use and heroin use risk behaviors 
among nonmedical users of prescription opioid pain 
relievers - United States, 2002-2004 and 2008-2010. Drug 
Alcohol Depend. 2013;132(1-2):95-100. doi:10.1016/j.
drugalcdep.2013.01.007
3. Van Zee A. The promotion and marketing of oxycontin: 
commercial triumph, public health tragedy. Am J 
Public Health. 2009;99(2):221-227. doi:10.2105/
AJPH.2007.131714
4. Sorg MH, Greenwald M. Patterns of drug-related 
mortality in Maine, 1997-2002. Maine Policy 
Review. 2003;12(1):84–96. Accessed May 12, 2021 https://
digitalcommons.library.umaine.edu/cgi/viewcontent.
cgi?article=1221&context=mpr
5. Simpson KJ, Moran MT, Foster ML, et al. Descriptive, 
observational study of pharmaceutical and non-
pharmaceutical arrests, use, and overdoses in 
Maine. BMJ Open. 2019;9(4):e027117. doi:10.1136/
bmjopen-2018-027117
6.	 Office	 of	 the	 Maine	Attorney	 General.	 Attorney	 General	
releases drug death report for 2019. Maine.gov. May 1, 
2020. Accessed August 4, 2020. https://www.maine.gov/
ag/news/article.shtml?id=2479607
7. Piper BJ, Desrosiers CE, Fisher HC, McCall KL, Nichols 
SD. A new tool to tackle the opioid epidemic: description, 
utility, and results from the Maine Diversion Alert Program. 
Pharmacotherapy. 2017;37(7):791-798. doi:10.1002/
phar.1952
8. Piper BJ, Desrosiers CE, Lipovsky JW, et al. Use and 
misuse of opioids in Maine: results from pharmacists, the 
prescription Monitoring, and the Diversion Alert programs. 
J Stud Alcohol Drugs. 2016;77(4):556-565. doi:10.15288/
jsad.2016.77.556
9. Simpson KJ, Moran MT, McCall KL, et al. Increasing 
heroin, cocaine, and buprenorphine arrests reported 
to the Maine Diversion Alert Program. Forensic Sci Int. 
2019;303:109924. doi:10.1016/j.forsciint.2019.109924
10. Diversion Control Division. Automation of Reports and 
Consolidated Orders System (ARCOS). Drug Enforcement 
Administration. Accessed July 1, 2020. http://www.
deadiversion.usdoj.gov/arcos/
11.	 Bokhari	 F,	 Mayes	 R,	 Scheffler	 RM.	 An	 analysis	 of	 the	
significant	 variation	 in	 psychostimulant	 use	 across	 the	
U.S. Pharmacoepidemiol Drug Saf. 2005;14(4):267-275. 
doi:10.1002/pds.980
11. United States Census Bureau. 2020. County Population 
Totals: 2010-2019. Accessed August 18, 2020. https://
www.census.gov/data/tables/time-series/demo/
popest/2010s-counties-total.html
12. Sevigny EL, Caces MF. When DAWN went dark: Can 
the Nationwide Emergency Department Sample (NEDS) 
fill	 the	 surveillance	 gap	 left	 by	 the	 discontinued	 Drug	
Abuse Warning Network (DAWN)? Drug Alcohol Depend. 
2018;192:201-207. doi:10.1016/j.drugalcdep.2018.07.043
13. Maine Opioid Treatment. Methadone. US. Accessed 
August 18, 2020. http://www.methadone.us/maine-opioid-
treatment/
14. Borron SW, Monier C, Risède P, Baud FJ. Flunitrazepam 
variably alters morphine, buprenorphine, and methadone 
lethality in the rat. Hum Exp Toxicol. 2002;21(11):599-605. 
doi:10.1191/0960327102ht303oa
15. Post S, Spiller HA, Casavant MJ, Chounthirath T, Smith 
GA. Buprenorphine exposures among children and 
adolescents reported to US Poison Control Centers. 
Pediatrics. 2018;142(1). doi:10.1542/peds.2017-3652
16. Sorg MH. Expanded Maine drug death report for 2018. 
Accessed August 18, 2020. https://assets.documentcloud.
org/documents/5955343/ME-2018-Annual-DD-Report-
finalR.pdf
17. Edwards LD. Bupenorphine in Wisconsin drivers: 
concerns for impairment? J Anal Toxicol. 2019;43(8):644-
650. doi:10.1093/jat/bkz068
18. Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-
Diehn C. Retention in medication-assisted treatment for 
opiate dependence: a systematic review. J Addict Dis. 
2016;35(1):22-35. doi:10.1080/10550887.2016.1100960
19. Ordway R. Methadone debates lack facts. Bangor Daily 
News. August 2, 2008. Accessed August 18, 2020. 
https://bangordailynews.com/2008/08/02/uncategorized/
methadone-debates-lack-facts/
20. Knudson HK. The supply of physicians waivered to 
prescribe buprenorphine for opioid use disorders in the 
United States: a state-level analysis. J Stud Alcohol Drugs. 
2015;76(4):644-654. doi:10.15288/jsad.2015.76.644
21. Collins LK, Pande LJ, Chung DY, Nichols SD, McCall KL, 
Piper BJ. Trends in the medical supply of fentanyl and 
fentanyl analogues: United States, 2006 to 2017. Prev 
Med. 2019;123:95-100. doi:10.1016/j.ypmed.2019.02.017
22. Philp M, Fu S. A review of chemical ‘spot’ tests: A 
presumptive	illicit	drug	identification	technique.	Drug	Test	
Anal. 2018;10(1):95-108. doi:10.1002/dta.2300
23. Cabrera FF, Gamarra ER, Garcia TE, et al. Opioid 
distribution trends (2006-2017) in the US Territories. 
PeerJ. 2019;7:e6272. doi:10.7717/peerj.6272
24. McCall KL, Tu C, Lacroix M, Holt C, Wallace KL, Balk J. 
Controlled substance prescribing trends and physician and 
pharmacy utilization patterns: epidemiological analysis of 
the Maine Prescription Monitoring Program from 2006 to 
2010. J Substance Use. 2013;18:467–475. doi:10.3109/1
4659891.2012.685794
25. HHS 42 CFR Part 2 Proposed Rule Fact Sheet. HHS.




Hyde et al.: Drug Arrests in Maine
Published by MaineHealth Knowledge Connection, 2021
